Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin.
Ohradanova-Repic A, Skrabana R, Gebetsberger L, Tajti G, Baráth P, Ondrovičová G, Praženicová R, Jantova N, Hrasnova P, Stockinger H, Leksa V. Ohradanova-Repic A, et al. Among authors: gebetsberger l. Front Immunol. 2022 Aug 23;13:958581. doi: 10.3389/fimmu.2022.958581. eCollection 2022. Front Immunol. 2022. PMID: 36081512 Free PMC article.
Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
Gattinger P, Kratzer B, Tulaeva I, Niespodziana K, Ohradanova-Repic A, Gebetsberger L, Borochova K, Garner-Spitzer E, Trapin D, Hofer G, Keller W, Baumgartner I, Tancevski I, Khaitov M, Karaulov A, Stockinger H, Wiedermann U, Pickl WF, Valenta R. Gattinger P, et al. Among authors: gebetsberger l. Allergy. 2022 Aug;77(8):2431-2445. doi: 10.1111/all.15305. Epub 2022 Apr 15. Allergy. 2022. PMID: 35357709 Free PMC article.
SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year.
Garner-Spitzer E, Wagner A, Kundi M, Stockinger H, Ohradanova-Repic A, Gebetsberger L, Schoetta AM, Gudipati V, Huppa JB, Kunert R, Mayrhofer P, Kreil TR, Farcet MR, Hoeltl E, Wiedermann U. Garner-Spitzer E, et al. Among authors: gebetsberger l. Front Med (Lausanne). 2022 Feb 15;9:822316. doi: 10.3389/fmed.2022.822316. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35242786 Free PMC article.
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
Wagner A, Garner-Spitzer E, Schötta AM, Orola M, Wessely A, Zwazl I, Ohradanova-Repic A, Weseslindtner L, Tajti G, Gebetsberger L, Kratzer B, Tomosel E, Kutschera M, Tobudic S, Pickl WF, Kundi M, Stockinger H, Novacek G, Reinisch W, Zielinski C, Wiedermann U. Wagner A, et al. Among authors: gebetsberger l. Front Immunol. 2022 May 12;13:889138. doi: 10.3389/fimmu.2022.889138. eCollection 2022. Front Immunol. 2022. PMID: 35634285 Free PMC article. Clinical Trial.
Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model.
Gattinger P, Kratzer B, Sehgal ANA, Ohradanova-Repic A, Gebetsberger L, Tajti G, Focke-Tejkl M, Schaar M, Fuhrmann V, Petrowitsch L, Keller W, Högler S, Stockinger H, Pickl WF, Valenta R. Gattinger P, et al. Among authors: gebetsberger l. Vaccines (Basel). 2024 Feb 23;12(3):229. doi: 10.3390/vaccines12030229. Vaccines (Basel). 2024. PMID: 38543863 Free PMC article.